Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2018

View Archived Issues

FDA expands approval of Gilotrif in NSCLC

SAAP-148 shows promise for combating multidrug-resistant bacteria

Prolong Pharmaceuticals gives update on ongoing projects

FDA approves of Trisenox injection for first-line treatment of acute promyelocytic leukemia

Eurocine Vaccines cleared to begin study of Immunose Flu

InflaRx presents company and pipeline overview

Nanoparticle-encapsulated rapamycin induces immune tolerance to restore immunotoxin activity

FDA grants orphan drug designation to BB-301 for oculopharyngeal muscular dystrophy

FDA accepts Sandoz's BLA for adalimumab biosimilar

LIDDS raises capital through direct share issue

Suzhou Kintor Pharmaceuticals patents mTOR and/or PI3K inhibitors

Japanese approval sought for Opdivo with Yervoy for unresectable or metastatic renal cell carcinoma

Aprinoia Therapeutics completes series B financing round

ValiRx reports phase II data on VAL-401 in late-stage NSCLC

Universite Jagellonne and Neurolixis divulge 5-HT1A receptor agonists

Janssen identifies novel TLR7 and/or TLR8 agonists

Y-mAbs commences phase III study of naxitamab in neuroblastoma with osteomedullary disease

LifeArc presents novel antivirals for HFMD

Novel HLA-G-targeting antibodies presented by Invectys

NHLBI initiates phase I study of HERV-E TCR transduced autologous T cells in renal cell carcinoma

MedImmune studies MEDI-5884 in stable coronary heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...